About Julian Long
Julian is a highly rated global M&A partner.
Julian headed the Financial News list of Europe’s top 10 M&A lawyers by deal value in 2020, came top of Mergermarket’s table of UK lawyers by deal value in 2018 and was named Financial News partner of the year in 2015. He combines this transactional work with strategic advice to boards of publicly traded companies on activism, capital raisings, corporate governance and crisis and risk management.
Julian has a long-standing excellent reputation as a board adviser, reflecting his broad experience across a range of sectors and geographies. He is particularly valued by clients for his relationship skills, which are evident in his calming influence and reassuring manner.
- Aon on its proposed merger with Willis Towers Watson.
- AstraZeneca on its acquisition of Alexion, its defence of Pfizer’s bid, the financing of its collaboration with Daiichi Sankyo, its collaboration with Merck and its acquisition of Acerta.
- Haleon on its spin from GSK.
- Novartis on its portfolio transformation including the asset swap with GSK (oncology, OTC and vaccines assets), the sale of its animal health business to Eli Lilly, the put of its stake in the consumer health joint venture to GSK and other M&A transactions.
- AVEVA Group on the offer by Schneider.
- Rentokil Initial on its acquisition of Terminix.
- Comcast on its successful public auction against 21st Century Fox for Sky.
- Aberdeen Asset Management on its merger with Standard Life.
- BP in relation to the acquisition of BHP's shale oil and gas business and in relation to the Gulf of Mexico.
- RELX on the simplification of its DLC structure.
- Cancer Research UK on the consortium arrangements behind the UK Centre for Medical Research and Innovation (UKCMRI).